Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Up 118.1% in March

Sunshine Biopharma, Inc. (NASDAQ:SBFM) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 971,000 shares, a growth of 118.1% from the February 29th total of 445,300 shares. Based on an average daily volume of 14,760,000 shares, the short-interest ratio is presently 0.1 days. Currently, 1.1% of the company’s stock are sold short.

Sunshine Biopharma Price Performance

NASDAQ:SBFM remained flat at $0.06 during midday trading on Thursday. 13,169,106 shares of the company were exchanged, compared to its average volume of 16,179,803. The firm has a 50-day moving average price of $0.12 and a 200-day moving average price of $0.23. Sunshine Biopharma has a 12 month low of $0.04 and a 12 month high of $1.40. The company has a market cap of $1.70 million, a PE ratio of -0.04 and a beta of 1.13.

Institutional Trading of Sunshine Biopharma

Institutional investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in Sunshine Biopharma in the first quarter worth about $31,000. Virtu Financial LLC acquired a new stake in Sunshine Biopharma in the 1st quarter worth approximately $34,000. Bank of Montreal Can purchased a new stake in Sunshine Biopharma during the 2nd quarter worth approximately $40,000. Two Sigma Investments LP acquired a new position in Sunshine Biopharma during the 3rd quarter valued at approximately $29,000. Finally, Citadel Advisors LLC purchased a new position in shares of Sunshine Biopharma in the fourth quarter worth $50,000. Institutional investors and hedge funds own 41.98% of the company’s stock.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents.